Harvey Goldberg
Cardiovascular Disease · New York, NYNPI 1376531780
Payments from drug & device makers
Across 56 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$176
- Pfizer$160
- Regeneron Healthcare Solutions, Inc.$151
- Boehringer Ingelheim$129
- Novartis$121
- Lilly USA, LLC$112
- plus $549 from 15 others
What the payments were for
- Food & beverage$1,399100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $176 |
| Pfizer | 3 | $160 |
| Regeneron Healthcare Solutions, Inc. | 5 | $151 |
| Boehringer Ingelheim | 6 | $129 |
| Novartis | 6 | $121 |
| Lilly USA, LLC | 6 | $112 |
| Amarin Pharma, Inc. | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Johnson & Johnson | 2 | $48 |
| Scpharmaceuticals Inc. | 1 | $41 |
| Biobeat USA Inc. | 1 | $39 |
| GSK | 2 | $36 |
| Novo Nordisk | 1 | $34 |
| Philips North America LLC | 1 | $32 |
| Cleerly, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Aegerion Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$125
How this compares
$1,399 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 304 | $303,161 |
| JardianceEmpagliflozin | 118 | $103,755 |
| Repatha SureclickEvolocumab | 69 | $62,443 |
| AtivanLorazepam | 11 | $49,907 |
| OzempicSemaglutide | 39 | $46,484 |
| EntrestoSacubitril/Valsartan | 27 | $31,260 |
| XareltoRivaroxaban | 28 | $31,253 |
| Praluent PenAlirocumab | 27 | $22,402 |
| Ezetimibe | 287 | $11,846 |
| FarxigaDapagliflozin Propanediol | 21 | $11,520 |
| MyrbetriqMirabegron | 18 | $11,202 |
| NexletolBempedoic Acid | 17 | $10,727 |
| Metoprolol Succinate | 416 | $7,782 |
| VascepaIcosapent Ethyl | 21 | $7,405 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $6,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $160 | $307,326353 claims |
| Boehringer IngelheimJardiance | $129 | $103,755118 claims |
| Novo NordiskOzempic | $34 | $46,48439 claims |
| NovartisEntresto | $121 | $31,26027 claims |
| Johnson & JohnsonXarelto | $48 | $31,25328 claims |
| GSKBreo Ellipta, Incruse Ellipta | $36 | $11,29929 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $11,20218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.